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Abstract: Metal complexes of the title ligand (L) containing Co(II), Ni(II), and Cu(II) were prepared and
characterized by elemental analysis, IP electronic spectroscopy and conductimetry. The new derivatives,
possessing the following formulae, CuL2(OH)2, NiL2CI2, and [Co2LC14]n showed in vitro antifungal activity
against Aspergillus and Candida spp.
Intoduction
1,3,4-Thiadiazole derivatives possess interesting biological activity probably conferred to them by the
strong aromaticity of this ring system, which leads to great in vivo stability and generally, a lack of toxicity
for higher vertebrates, including humans. When diverse functional groups that interact with biological
receptors are attached to this ring, compounds possessing oustanding properties are obtained. Except for
some antibacterial sulfonamides (albucid and globucid), no longer used clinically, but which possessed
historical importance, the most interesting examples are constituted by 5-amino-l,3,4-thiadiazole-derivatives
such as the thiol 1, a compound used as radioprotective agent, as well as an investigational antitumor
4 and
gastroprotective drug; acetazolamide 2, which was the first non-mercurial diuretic drug,
69 used clinically
thereafter as antiglaucoma, antiepileptic
11 or antiulcer drug,
1 together with a large series of its congeners
derived from 5-amino-1,3,4-thiadiazole-2-sulfonamide 3.
9
N---N
1" R=H, Z=SH
2: R=Ac, Z=SO2NH2
3: R=H, Z=SO2NH2
These compounds, have also been investigated as complexing agents,
316 in order to obtain
substances with a diversified biological activity, conferred to them among others by the presence of the metal
ions, except for that of the thiadiazole ligand. Thus, some metal complexes of ligands of type 1-3 have been
recently reported as in vitro inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), 1’14’16 whereas
m vivo studies showed good antiepileptic action for some Cu(II) and Zn(II) complexes of the sulfonamide
type ligands.
TM Finally, some 2,5-disubstituted-l,3,4-thiadiazoles as well as their Cu(II) complexes were
16h reported to act as fungitoxic agents.
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Recently, another group of biologically active 1,3,4-thiadiazoles was reported by us.
17 5-(2-
Aminoethyl)-2-amino-l,3,4-thiadiazole 4 and some of its positively charged pyridinium derivatives showed
very good activatory effects on carbonic anhydrase,
17 making such compounds attractive candidates for the
development of pharmacological agents for the treatment of CA defficiency syndrome, a rare but dramatic
genetic disease which is caused by the lack ofisozyme CA II in the human organism. 8’9
As 4 possesses an interesting donor atoms system besides its prominent biological activity, 17’9 a
study for preparation and biological assay of some of its metal complexes was initiated in our laboratory.
Fungitoxicity has not been investigated previously for amines of type 4, and since many imidazoles and
triazoles such as ketoconazole, fluconazole, clortrimazole, etc possess outstanding fungistatic properties,
being widely used clinically,
2 it appeared of interest to test thiadiazole 4 and some of its metal complexes for
this type of biological activity. In this paper we report the synthesis of Co(II), Ni(II) and Cu(II) complexes of
ligand 4, and their activity as fungistatic agents against Aspergillus and Candida spp.
Materials and Methods
Infrared spectra were recorded in CsBr pellets with a Nicolet 2DXFT-IR apparatus. Electronic
spectra were recorded by the diffuse reflectance technique using MgO as a reference material. Conductometry
was done in DMF solution with a Radelkis 1200K/1 apparatus at 25C. Elmental analyses were done by
combustion (C,H,N,S) with an automated Carlo Erba analyser, or by atomic absorption spectroscopy for the
metal ions. Ligand 4 was prepared as described in the literature.
7 Metal salts and solvents were analytical
grade (from Merck or Aldrich) and were used without further purification.
Synthesis ofcomplexes 5-7
All complexes reported in this paper have been synthesised according to the following general procedure:
methanolic solutions containing the metal chloride (CuC12 2H20, CoC12 6H20, NiCI 6HO) and the
heterocyclic diamine, 4, (L.2HC1),
17 were mixed with stirring in molar ratios of 1:1 and 1:2, respectively. The
dihydrochloride of amine 4 was used in synthesis, due to its good methanol solubility.
17 The resulting mixture
was treated with a stoichiometric amount of triethylamine (in order to neutralize the HC1 of the
dihydrochloride) and the obtained mixture was heated for 60 min. on a water bath. The complexes precipitated
from these solutions, were filtered, washed with diethylether and dried in vacuum. The following coordination
compounds were synthesised and characterised: CuL2(OH)2 (green blue) 5, NiL2C12 (blue) 6, and Co2LC14
(red brown) 7. In the above formulas L stands for the corresponding diamino ligand. It is to note that, even
when working in molar ratio MClx: L of 1:1 or 1:2, only the above mentioned compounds were obtained.
Copper (II) complex 5’ non-electrolyte, IR (CsBr), cm1, 470, 617, 763, 927, 1069, 1127, 1348, 1456, 1482,
1512, 1600, 2361, 2952. UV-VIS (MgO), cmlx10
"3 "7.0, 11.0, 15.7, 23.1, 26.3. Analysis:found, %Cu, 16.35;
%C, 25.17; %H, 4.46, %N, 29.24, %S, 16.48; CuCsH18NsS202; requires %Cu, 16.58; %C, 24.87; %H, 4.66,
%N, 29.02, %S, 16.58.
Nickel (II) complex 6: non-electrolyte, IR (CsBr), cm1, 440, 624, 862, 941, 1127, 1162, 1283, 1351, 1422,
1510, 1605, 2368, 2952, UV-VIS (MgO), cmlx10"3, 10.0, 17.5, 20.1, 25.3. Analysis:found, %Ni, 14.01" %C,
23.17; %H, 3.66, %N, 26.24, %S, 15.48; %C1, 16.75 NiCsH16N8S2C12 requires %Ni, 14.11; %C, 22.96;
%H, 3.82, %N, 26.79, %S, 15.31; %C1, 16.98.
Cobalt (II) complex 7" electrolyte, IR (CsBr), cm1, 316, 450, 526, 580, 859, 971, 1127, 1157, 1340, 1419,
1532, 1605, 2361, 2952, UV-VIS (MgO), cm’lxl0-3, 9.1, 11.2, 14.3, 18.8, 21.5, 26.3. Analysis:found, %Co,
27.89; %C, 12.17; %H, 1.66, %N, 14.14, %S, 7.48; %C1, 34.88, Co2C4H8NaSC14; requires %Co, 29.20; %C,
11.88; %H, 1.98, %N, 13.86, %S, 7.92; %C1, 35.15.
Assay ofmgistatic activity ofcompounds 4-7
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The fungistatic activities of derivatives 4-7 were determined by a modification ofthe growth method
21 recently
reported by us,
22 utilizing two Aspergillus and one Candida spp. The fungi were cultivated in agar plates at
25C, in the absence and in the presence of compounds 4-7, in concentrations ranges of 10
-3 10
-7 M
(solutions in DMSO). No significant fungistatic effects were observed at concentrations of 10
-6 and 10
.7 M of
the new compounds, except for the Cu(II) derivative 5 (the most active in the series), which showed
interesting inhibitory activity in micromolar concentrations too. Percentual inhibition ofgrowth was calculated
with the following formula:21’22
% inhibition 100 x (Dc-Di)/Dc
where Dc represents the average diameter of the fungi colony in the control plate after 48 hours, whereas Di
the same parameter in the presence oftested compound.
Results and Discussion
Due to the complicated donor system of the ligand 4, at least four different more common
complexation modes are probable, depicted as I-IV in the formulas bellow. The most favourable one for
mononuclear complexes would be II or IV, due to the stability of six membered cycles formed in these cases,
while I and III should lead to less stable four membered rings. From IR data discussed shortly, we ruled out
coordination of types III or IV, as among others, no M-S bands were observed in the IR spectra. From the
stereochemical point of view it is also hardly possible a coordination of type IV. Thus, as for histamine and
histidine complexes, the most probable coordination mode is probably II, involving the aminoethyl NH2 group
and the endocyclic nitrogen N-4 ofthe heterocyclic ring
23
H2 H2
NH2
In the IR spectra of complexes 5-7 the large stretching vibrations of the ammonium bands from the
IR spectrum of 4 (as dihydrochloride salt),
17 around 3000 cm, are absent, due to the involvement of the free
NH2 groups in coordinating the metal ions. Characteristic vibrations of the ligand (SNH: at 1630 cm4, Vc=N at
1564 cm
4 in the spectrum of 4) are also present in the spectra of complexes 5-7, but shifted towards lower
wavenumbers as compared to the spectrum of 4. Thus the thiadiazolic band appears at 1510 1532 cm
1
(Vc=N) in the spectrum ofthese complexes. The shiR with 25-35 cm
1 towards lower wavenumbers of the NH:
and C=N vibrations in the IR spectra of the complexes is indicative that the coordination of type II or I
proposed above might describe the behaviour of 4 in its metal complexes. The coordination by two types of
nitrogen atoms is also supported by the existence of large bands in the range 200-600 cm
4 in the spectra of
complexes 5-7, presumably due to M-N vibrations. A band centred at 470 cm
4 was observed for the Cu(II)
complex 5, at 440 cm
"1 for the Ni(II) complex 6 and several peaks for the Co(II) complex $, at 316, 450 and
526 cml.
4
Supplementary stereochemical information for the new complexes 5-7 was obtained from the
absorption electronic spectra ofthe three compounds.
In the electronic spectrum of the Cu(II) derivative 5, two large bands were observed: i) the first one
is located in the range 5-18 xl03 cm
4 and offers information about d-d- transitions. By deconvolution using
the Gauss method,
25 the following transition bands were identified, at 7 xl03, 11 xl03, and 15.7 x103 cm1,
respectively. The lowest energy, according to the dx2. y2 dz2, transitions, is characteristic for the copper (II)
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ion in a (pseudo)-octahedral configuration.
25 The band appeared at a slightly higher energy due to the
involvement of the 4s orbital in the coordination sphere, ii) The second transition observed in the range 18-25
xl 03 cm
-1 can be attributed to charge transfer bands.
25
The diffuse reflectance spectrum ofthe nickel complex 6 is characteristic for a (pseudo)-octahedral
arrangement with the following transition bands: v 10 xl0 cm (3T2g ::: 3A2g), v2:17.5 xl0 cm (3Tlg (F)
<:= 3AEg), v3: at higher energies (charge transfer energy). After deconvoiution the first band (vl) was splitted in
two components and the second band (v2) in three components, this supplementary division being probably
due to the low simetry ofthe ligand field and to the non-equivalence ofthe donor atoms.25’26
The electronic spectrum of the Co(II) complex 7 possibly contains two overlapped bands of two
chromophores in different stereochemistries. The presence of an intense band at 15 xl0 cm
"I confirms the
tetrahedral sterochemistry, while other bands at 11.2 xl03, 16.3 xl03, and 21.5 xl0 cm"I, respectively, are
characteristic for a (pseudo)-octahedral configuration of the Co(II) ion.
27 It is difficult to formulate this
compound as octahedra! cation: tetrahedral anion complex, (due to its brown-red color characteristic of
polynuclear complexes of Co(II))
25 as the presence of the tetrahedral anion [CoCl4]
2" would imprim an imense
blue colour to it.25’27 Thus, the polynuclear structure shown below is proposed, whereas the other two
mononuclear complexes were formulated as containing octahedral Cu(II) and Ni(II) ions.
H2N X
SN//N "’
X NH2
5: M=Cu(II), X=OH;
6: M= Ni(ll), X=Cl
\
!,
.Co
gl NH2
CO
7 """ k
The fungistatic activities of derivatives 4-7 against two Aspergillus species and Candida albicans are
presented in Table I. Clotrimazole 8, a topically effective fungistatic agent with clinical applications was used
20,28 as a standard in these assays.
As seen from the data of Table I, the thiadiazole 4 is much less effective as fungitoxic agent as
compared to clotrimazole, an imidazole derivative with a potent such activity, against all three fungi species
investigated. The metal complexes 5-7 already show an increased fungitoxic activity (at the concentration of
10 laM, for which the data of Table I stand). At 0.1 laM concentrations no such activity was observed for
the complexes, except for the Cu(II) derivative 5 (data not shown). At 10 laM, significant inhibitions of
growth were detected for 5, which is almost as effective as clotrirnazole against A. niger, slightly more
effective against A. flavum, and much less effective against Candida. The other two complexes showed a
modest activity, which is anyhow greater against the Apergillus pp. as compared to Candida. The metal ion
inducing best fungitoxic activity was Cu(II), followed by Co(II) and Ni(II), which possessed comparative
efficiency.
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As for the mechanism of action ofthese derivatives, probably it is similar to that ofthe imidazole, and
triazole derivatives used clinically, i.e., the inhibition of sterol 14-c-demethylase, a microsomal cytochrome P-
450 dependent enzyme system.
29 These compounds thus impair the biosynhesis of ergosterol for the
cytoplasmic membrane and lead to the accumulation of 14-t-methyl sterols which may disrupt the close
packing of acyl chains of phospholipids, impairing the function ofmembrane-bound enzymes and inhibiting
growth.
29,3
Table I: Inhibition of growth with derivatives 4-7 and clotrimazole 8 (at concentrations of 10 laM) of
A6pergillus and Candida spp. after 48 hours, at 25C.
Compound % Inhibition
Aspergillus niger Aspergillusflavum Candida albicans
4 22.5+3.6 14.1+_2.7 5.2+1.4
5 78.9+5.4 83.6+4.2 42.1+_2.8
6 43.7+3.0 29.5+4.1 13.1+3.5
7 44.9+3.7 31.6+_2.8 10.3+4.0
8 88.5+_5.2 79.0+_4.2 66.7+_5.5
aMean + standard error from 10 plates.
Acknowledgments. This research was financed in part from the EU gram ERB CIPDCT 940051.
References
1. Part 8 of this series: M.Brezeanu, M.Badea, D.Marinescu; N.Stanica, M.A.Ilies, and C.T.Supuran,
Rev.Roum. Chim., in press.
2. G.Kornis, "l,3,4-Thiadiazoles", in "Comprehensive Heterocyclic Chemistry", A.R.Katritzky Ed., Pergamon
Press, 1984, Vol. 6, Part 4B, pp. 545-578.
3. M.Davis, Org. Compd. Sulphur, Selenium, Tellurium 1979, 5, 440-449.
4. K.Lu and T.Loo, Cancer. Chemother. Pharmacol., 1980, 4, 275-282.
5. K.Kusterer and S.Szabo, Eur. J. Pharmacol., 1987, 141, 7-15.
6. R.O.Roblin, and J.W.Clapp, J.Am.Chem.Soc., 1950, 72, 4890-4892
7. T.H.Maren, Physiol.Rev., 1967, 47, 595-782.
8. T.H.Maren, "The links among biochemistry, physiology and pharmacology in carbonic anhydrase mediated
systems", in "Carbonic Anhydrase From Biochemistry and Genetics to Physiology and Clinical Medicine",
F.Botr6 et al. Eds., VCH, Weinheim, 1991, pp. 186-207.
9. a) C.T.Supuran, "Carbonic anhydrase inhibitors", in "Carbonic Anhydrase and Modulation of Physiologic
and Pathologic Processes in the Organism", I.Puscas Ed., Helicon, Timisoara, 1994, pp. 29-111; b)
T.H.Maren, B.W.Clare and C.T.Supuran, Roum. Chem. Quart. Rev., 1994, 2, 259-282.
10. T.H.Maren, J.Glaucoma, 1995, 4, 49-62.
11. D.M.Woodbury, in "Antiepileptic Drugs: Mechanisms of Action", G.H.Glaser et al. Eds., Raven Press,
New York, 1980, pp. 617-633.
12. I.Puscas and C.T. Supuran, "Farmacologia Clinica da Ulcer Peptica" in "Aparelho Digestivo", J. Coelho
Ed., Rio de Janeiro, MEDSI, 1996, pp. 1704-1734
13. a) T.C.Downie, W.Harrison, E.S.Raper and M.A.Hepworth, Acta Cryst., 1972, B28, 1584-1590; b)
E.S.Raper, R.E.Oughtred and I.W.Nowell, Inorg.Chim.Acta, 1983, 77, L-89-L-94; c) E.S.Raper,
Coord.Chem.Rev., 1994, 129, 91-156.
14. a) M.Brezeanu, R.Olar, G.Manole and C.T.Supuran, Rev.Roum.Chim., 1992, 37, 425-431; b)
231Vol. 3, No. 5, 1996 Synthesis and Biological Activity ofMetal Complexes
(" l’.Supuran, F.Cimpoesu, G.Manole and M.Brezeanu, Rev.Roum.(’him., 1992, 37, 959-964; c) C.T.Supuran,
(" i.Lepadatu, R.Olar, A.Meghea and M.Brezeanu, Rev.Roum.(’him., 1993, 38, 1509-1517. . a) U.Hartmann and H.Vahrenkamp, blorg.Chem., 1991, 30, 4676; b) S.Ferrer, J.G.Haasnoot, R.A.G de
G;aaft J.Reedijk and J.Borrhs, htorg.(’him.Acta, 1992, 192, 129-138; c) G.Alzuet, L.Casella, A. Perotti and
.l! orms, J.(’hem.Soc.Dalton Trans., 1994, 2347-2351; d) GAlzuet, J.Casanova, J.A.Ramirez, J.Borrhs and
() Carugo, J.btorg.Biochem., 1995, 57, 219-234.
’. a) A.Antoniu, C.T.Supuran, and M.Brezeanu, Rev.Roum.(’him., 1995, 40, 203-207; b) L. Sumalan,
J.Casanova, G.Alzuet, J.Borrhs, A.Castineiras and C.T.Supuran, J.Inorg.Biochem., 1996, 62, 31" c)
C.T.Supuran, Metal Based Drugs, 1995, 2, 327-330; d) C.T.Supuran, Metal Based Drugs, 1995, 2, 331;
e) C.T.Supuran, Metal Based Drugs, 1991i, 3, 25-30; f) J.Borras, T.Cristea and C.T.Supuran, Main Group
Met. Chem., 1996, 19, 339; g) J.Borras, J.Casanova, T.Cristea, A.Gheorghe, A.Scozzafava, C.T.Supuran
and V.Tudor, Metal Based Drugs, 1991i, 3, 143; h) K.N.Thimmaiah, G.T.Chandrappa, W.D.Lloyd and
C.Parkanyi, Inorg.Chim.Acta 1985, 107, 1.
17. C.T.Supuran, M.Barboiu, C.Luca, E.Pop, M.E.Brewster and A.Dinculescu, Eur.J.Med. Chem., 1991i,
31,596.
18. a) W.S.Sly, D.Hewett-Emmett, M.P.Whyte and R.E.Tashian, Proc.Nat.Acad.Sci USA, 1983, 80,
2752; b) W.S.Sly, S.Sato and X.L.Zhu, Clin.Biochem., 1991, 24, 311.
19. C.T.Supuran and I.Puscas, "Carbonic Anhydrase Activators", in "Carbonic Anhydrase and Modulation
of Physiologic and Pathologic Processes in the Organism", I.Puscas Ed., Helicon, Timisoara, 1994, pp.
112-145.
20. J.E.Bennett, "Antifungal agents", in "The Pharmacological Basisf Therapeutics", 8th Edition,
A.G.Gilman, TW Rall, AS Nies and P Taylor Eds., Pergamon Press, New York 1990, pp. 1165-1181.
21. J.G.Horsfall, Bot.Rev., 1945, 11, 357.
22. C.T.Supuran, G.Loloiu and G.Manole, Rev.Roum. Chim., 1992, 37, 1181.
23. a) M.Forster and H.Vahrenkamp, Chem.Ber., 1995, 128, 541; b) T.Matsukura, Y.Nishimura,
T.Ohtani, M.Sawada and K.Shibata, Chem.Pharm.Bull., 1990, 38, 3140; c) T.Gajda, B.Henry and
J.J.Delpuech, Inorg. Chem., 1995, 34, 2455; d) T.Gajda, B.Henry and J.J.Delpuech, J. Chem. Soc.Faraday
Trans., 1994, 89, 157.
24. K.Nakamoto, "Infrared Spectra of Inorganic and Coordination Compounds", Pergamon Press, New York,
1986, pp. 115-126.
25. A.B.P. Lever, "Inorganic Electronic Spectroscopy", Elsevier Publishing Co., Amsterdam, 1984, pp.
178-196.
26. L.Sacconi, F.Mani and A.Bencini, "Nickel", in "Comprehensive Coordination Chemistry",
G.Wilkinson, R.Gillard and J.McCleverty Eds., Pergamon Press, Oxford, 1987, Vol. 5, pp. 1-347.
27. L.Banci, A.Bencini, C.Benelli, D.Gatteschi and C.Zanchini, Struct.Bonding, 1982, 52, 37-79.
28. J.N.Galgiani, Clin.Lab.Med., 1989, 9, 269.
29. H. Vanden Bossche, Drug Dev Res, 1981i, 8, 287.
30. J.M.T.Hamilton-Miller, Adv.Appl.Microbiol., 1974, 17, 109.
Received: September 13, 1996 Accepted: September 17, 1996
Received in revised camera-ready format: September 24, 1996
232